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Background: The aim of this study was to evaluate the safety and analgesic efficacy of polmacoxib 2 mg versus placebo in a su-
periority comparison or versus celecoxib 200 mg in a noninferiority comparison in patients with osteoarthritis (OA).
Methods: This study was a 6-week, phase III, randomized, double-blind, and parallel-group trial followed by an 18-week, single 
arm, open-label extension. Of the 441 patients with knee or hip OA screened, 362 were randomized; 324 completed 6 weeks of 
treatment and 220 completed the extension. Patients were randomized to receive oral polmacoxib 2 mg (n = 146), celecoxib 200 mg 
(n = 145), or placebo (n = 71) once daily for 6 weeks. During the extension, all participants received open-label polmacoxib 2 mg. 
The primary endpoint was the change in Western Ontario and McMaster Universities (WOMAC)-pain subscale score from baseline 
to week 6. Secondary endpoints included WOMAC-OA Index, OA subscales (pain, stiffness, and physical function) and Physician’s 
and Subject’s Global Assessments at weeks 3 and 6. Other outcome measures included adverse events (AEs), laboratory tests, vital 
signs, electrocardiograms, and physical examinations. 
Results: After 6 weeks, the polmacoxib-placebo treatment difference was –2.5 (95% confidence interval [CI], –4.4 to –0.6; p = 
0.011) and the polmacoxib-celecoxib treatment difference was 0.6 (CI, –0.9 to 2.2; p = 0.425). According to Physician’s Global As-
sessments, more subjects were “much improved” at week 3 with polmacoxib than with celecoxib or placebo. Gastrointestinal and 
general disorder AEs occurred with a greater frequency with polmacoxib or celecoxib than with placebo. 
Original Article    Clinics in Orthopedic Surgery 2017;9:439-457   •  https://doi.org/10.4055/cios.2017.9.4.439
Copyright © 2017 by The Korean Orthopaedic Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinics in Orthopedic Surgery • pISSN 2005-291X    eISSN 2005-4408
Received June 5, 2017; Accepted September 21, 2017
Correspondence to: Sangsook Cho, PhD
Clinical Research Department, CG Pharmaceuticals, Inc., 4 Orinda Way, Suite 100-D, Orinda, CA 94563, USA
Tel: +1-925-257-7036, Fax: +1-925-257-7036, E-mail: scho@cgxinc.com
440
Lee et al. Phase III Efficacy and Safety of Polmacoxib for Osteoarthritis
Clinics in Orthopedic Surgery • Vol. 9, No. 4, 2017 • www.ecios.org
Osteoarthritis (OA) is a progressive, whole joint, inflam-
matory disease that involves the breakdown and damage 
of cartilage and surrounding bone tissues and is associated 
with increased swelling and pain.1) There are approxi-
mately 54.4 million adults with doctor-diagnosed arthritis 
in the United States, including over half of the population 
above 50 years old. The most common form of arthritis 
is OA and about 30% of adults with obesity have doctor-
diagnosed arthritis.2) Given the rapidly ageing population 
and widespread obesity problem, the prevalence of OA is 
predicted to increase.
As there is no cure for OA, treatment plans are 
based on ways to manage pain and improve function. 
These plans include exercise and weight control, rest and 
joint care, surgery, and medication for pain relief.3) Cur-
rently, the most widely prescribed medications for OA are 
nonsteroidal anti-inflammatory drugs (NSAIDs); however, 
traditional NSAIDs carry a high risk of adverse events 
(AEs), including serious gastrointestinal (GI) diseases.4) 
NSAIDs inhibit cyclooxygenase (COX) enzymes, 
which play a role in the regulation of inflammation. COX-
1 is thought to protect the GI mucosa by the synthesis of 
prostaglandin,5,6) while COX 2 expression is increased by 
inflammation and involved in both inflammation and 
pain pathways.7) Conventional first generation NSAIDs are 
nonselective, inhibiting both COX-1 and COX-2, mean-
ing that GI lesions may accompany their effects to reduce 
inflammation and pain.5) 
Compounds exhibiting greater COX-2 selectivity 
are thought to reduce damage to the GI tract by allowing 
the synthesis of protective prostaglandins through COX-
1, while simultaneously maintaining anti-inflammatory 
effects by inhibiting COX-2. This led to the development 
of COX-2 selective drugs such as celecoxib and rofecoxib, 
which were reported to reduce GI-related AEs compared 
with conventional NSAIDs.8,9)
However, some studies have demonstrated an in-
creased risk of adverse cardiovascular (CV) events, includ-
ing blood pressure elevation and myocardial infarction, 
with COX inhibition.10,11) The health concerns associated 
with traditional NSAIDs and COX-2 inhibitors have led to 
confusion around the use of COX-2 inhibitors12) and pro-
vide strong rationale for the development of safer NSAIDs 
with fewer AEs on the GI tract and CV system.
Recently, a new COX-2 inhibitor, polmacoxib 
(CG100649; Acelex), has been developed.13,14) Unlike other 
NSAIDs, polmacoxib has a dual mode of action: inhibition 
of COX-2 and binding to carbonic anhydrase (CA) with 
high affinity.15) A key function of CA is to regulate the pH 
level in the body through the interconversion between car-
bon dioxide and bicarbonate. Where COX-2 and CA coex-
ist, the high-affinity binding of polmacoxib to CA reduces 
the COX-2 inhibitory activity of polmacoxib. Preliminary 
experiments have shown the COX-2 inhibitory activities 
of polmacoxib with varying amounts of CA in the sys-
tem.16) Since the CV side effects of traditional NSAIDs and 
COX-2 inhibitors are associated with COX-2 inhibition in 
the CV system where CA is abundant,17) it is theoretically 
possible that the dual action mechanism of polmacoxib 
may minimize the adverse CV effects of COX-2 inhibition, 
although supportive clinical evidence is currently lacking. 
Importantly, low-dose administration of polmacoxib is 
believed to have a negligible effect on overall CA function 
in the circulatory system, despite polmacoxib theoretically 
remaining in a combined state with CA.18)
The aim of this study was to evaluate the safety and 
analgesic efficacy of polmacoxib 2 mg versus placebo in 
a superiority comparison or versus celecoxib 200 mg in 
a noninferiority comparison, when administered once 
daily over 6 weeks in subjects with OA of the hip or knee. 
To reflect the lowest value of expected outcome to show 
the clinical and statistically significant difference between 
treatment groups, a number of studies on OA pain use 
a 10% noninferiority margin for chronic pain; as such, a 
prespecified noninferiority margin of 10% was used for 
the noninferiority analysis between polmacoxib and cele-
Conclusions: Polmacoxib 2 mg was relatively well tolerated and demonstrated efficacy superior to placebo and noninferior to 
celecoxib after 6 weeks of treatment in patients with OA. The results obtained during the 18-week trial extension with polmacoxib 
2 mg were consistent with those observed during the 6-week treatment period, indicating that polmacoxib can be considered safe 
for long-term use based on this relatively small scale of study in a Korean population. More importantly, the results of this study 
showed that polmacoxib has the potential to be used as a pain relief drug with reduced gastrointestinal side effects compared to 
traditional nonsteroidal anti-inflammatory drugs for OA.
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coxib in this study. If the upper boundary of the one-sided 
97.5% confidence interval (CI) is within the prespecified 
noninferiority margin, the null hypothesis can be rejected 
in favor of the alternative hypothesis, which means that the 
polmacoxib group is noninferior to the celecoxib group. 
An 18-week trial extension, in which all participants re-
ceived open-label polmacoxib 2 mg once daily, was con-
ducted to provide supporting safety and efficacy evidence.
METHODS
Study Design and Conduct
This was a multicenter, phase III, randomized, double-
blind, double-dummy, placebo- and active comparator-
controlled, and parallel-group trial. After providing in-
formed consent, subjects who were referred from primary 
care, entered into a 14-day washout period, in which 
subjects were required to discontinue existing treatment 
with NSAIDs and/or other analgesic medications. Subjects 
could take rescue medication (acetaminophen 650 mg/
day) during the washout and follow-up periods. Rescue 
medication was not allowed during the treatment period 
or within 24 hours before a clinic visit. 
After completion of the washout period, at visit 2 
(baseline), subjects meeting the inclusion and exclusion 
criteria were randomized into the study according to their 
order of enrollment, using a stratified block randomiza-
tion method for each site. Subjects were randomly as-
signed in a 2:2:1 ratio by an independent statistician using 
the SAS ver. 9.1 (SAS Institute Inc., Cary, NC, USA) and 
distributed by Interactive Web Response Service to receive 
either polmacoxib 2 mg, celecoxib 200 mg, or placebo 
once daily after breakfast over a 6-week treatment period. 
Investigational drugs were produced and packaged to 
maintain study blinding, and were supplied by the spon-
sor to an institutional pharmacist at each investigational 
site. Polmacoxib 2 mg, celecoxib 200 mg, and their respec-
tive placebos were identical in appearance and weight. To 
maintain blinding for both the subjects and investigators, 
study medications were labeled in an identical manner. 
To maintain double-blinding, identical double dummy 
placebos were used. The specific codes for each treatment 
group were kept in a sealed place by the sponsor and in-
vestigators, and were not to be opened until database lock 
and completion of the treatment assignment unblinding 
procedure.
During the 6-week treatment period, subjects re-
turned for study visits at week 3, week 6, and week 8, 
which was the final follow-up visit for subjects who did 
not agree to participate in the extended safety period. At 
each visit, efficacy was assessed by the Western Ontario 
and McMaster Universities (WOMAC)-OA index as well 
as the Subject’s Global Assessment (SGA) and Physician’s 
Global Assessment (PGA). Samples for evaluation of phar-
macokinetics were collected at baseline, week 6, and week 
8. Standard safety assessments, including serology testing, 
were conducted throughout the 6-week period. 
The 6-week treatment period was followed by an 18-
week open-label extended safety period in which subjects 
had the option to participate; for subjects who agreed, 
a separate informed consent was required at the week 6 
visit. All subjects who participated received polmacoxib 2 
mg. During this period, subjects returned for study visits 
at week 12, week 18, week 24, and week 26, which was 
the final follow-up visit for subjects participating in the 
extended safety period. Efficacy assessment, pharmacoki-
netic sample collection, and safety assessment were done 
at specified visits during the 18-week period. All subjects 
completed a follow-up visit 2 weeks after discontinuation 
of study treatment for any reason.
Eligibility Criteria
Subjects eligible for this trial were either male or female 
(aged ≥ 20 years) with a clinical diagnosis of knee or hip 
OA according to clinical and imaging criteria specified 
by the American College of Rheumatology (ACR) guide-
lines.19,20) Subjects must have had chronic pain for ≥ 3 months 
from OA and an ACR global functional status of I, II, or 
III (excluding IV).21) Other inclusion criteria were as fol-
lows: screening and baseline (predose) mean WOMAC-
pain score in the index joint between 4 and 8; blood 
chemistry within twice the normal range; urinalysis within 
normal limits, macroscopic evaluation showing no blood; 
agreement to use double barrier contraception during the 
study period and for 3 months afterwards; able to read, 
understand and follow the study documents; willing to 
limit alcohol intake to ≤ 2 drinks per day.
Subjects were excluded, discontinued, removed 
from the trial and not considered in the per-protocol and 
modified intent-to-treat (ITT) populations for analysis if 
they met any of the following criteria: use of any analgesics 
except the study medication or acetaminophen during the 
study; use of anticoagulants within 2 weeks of screening; 
use of corticosteroids, herbal medicines, traditional Ko-
rean medicines, nutraceuticals, glucosamine, and/or chon-
droitin sulfate; requirement for knee or hip arthroplasty 
within 2 months of screening or anticipating any need for 
a surgical procedure on the index joint during the study; 
hypersensitivity or allergy to NSAIDs; history of nasal 
polyps, bronchospasm, urticaria, or anaphylactic shock; 
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history of New York Heart Association stage II–IV con-
gestive heart failure, ischemic heart disease, uncontrolled 
hypertension, peripheral arterial disease, and/or cerebro-
vascular disease; pregnancy, breast-feeding, or expecting 
conception within the duration of the study; active ulcer, 
GI bleeding, ulcerative colitis, or severe renal, hepatic, or 
coagulant disorder within 6 months prior to randomiza-
tion; ongoing chronic symptoms or psychiatric disorders 
preventing compliance with study procedures, except for 
subjects who were physically healthy and had been receiv-
ing the specified allowed drugs for ≥ 3 months; use of 
corticosteroids, intra-articular steroids or hyaluronic acid 
injections within 1 month of screening; chemotherapy 
within 5 years; or a Chinese traditional arthritis treatment 
within 1 week of screening. 
Patients with stable hypertension for ≥ 3 months 
prior to screening, treated with antihypertensive medica-
tion, were permitted to participate in the study. 
Efficacy Assessments 
Efficacy was evaluated by the WOMAC arthritis index 
questionnaire (which was validated in OA patients and in 
Koreans),22,23) the PGA and SGA,24) and discontinuation 
from the study owing to a lack of analgesic efficacy. The 
numerical rating scale version of the WOMAC was used, 
with the subject assessing each question using an 11-point 
(0 to 10) numerical rating scale, and the total index score 
being represented by the sum of the component item 
scores. A higher WOMAC score represents worse symp-
tom severity. The primary endpoint was the change in the 
WOMAC-pain subscale (five items, total score 0 to 50) in 
the index joint at week 6 versus day 1 (predose baseline). 
Secondary endpoints included the change in WOMAC-
pain at week 3 and changes in WOMAC-stiffness (two 
items, total score 0 to 20), WOMAC-physical function 
(17 items, total score 0 to 170), WOMAC-OA index (24 
items, total score 0 to 240), and SGA and PGA tests at 
both weeks 3 and 6. SGA and PGA tests were based on a 
7-point Likert scale, assessing the overall condition asking 
the following question, “please choose a number that best 
represents the condition of the pain area during the past 
week.”
Safety Assessments
Safety assessments included the number of AEs, includ-
ing serious AEs (SAEs), treatment-emergent AEs (TEAEs; 
a condition that was not present prior to treatment with 
study medication, but appeared following treatment), 
deaths, and AEs leading to discontinuation. Other safety 
assessments included complete physical examinations, 
vital signs, 12-lead electrocardiograms and clinical labora-
tory tests (for hematology, clinical chemistry, coagulation, 
and urinalysis). Plasma and whole blood samples were 
taken for the pharmacokinetic assessment of polmacoxib 
after breakfast and administration of study drugs at day 1, 
weeks 6, and 8 for subjects who participated in the main 
6-week treatment period only, and at day 1, weeks 6, 24, 
and 26 for extension period participants. 
For subjects who participated in the 6-week treat-
ment period only, safety assessments were conducted at 
weeks 3, 6, and 8 (follow-up visit). For trial extension par-
ticipants, safety assessments were conducted at weeks 3, 6, 
12, 18, 24, and 26. 
Statistical Analysis
Calculation of sample size
Based on the International Conference on Harmonisation 
guideline E1,25) guidelines for noninferiority clinical trials 
of the U.S. Food and Drug Administration,26) and other 
similar study,27) the standard deviation and noninferiority 
margin were conservatively chosen for the calculation of 
sample size. For evaluation of noninferiority between pol-
macoxib and celecoxib for analgesic efficacy, the following 
parameters were used to calculate the sample size needed: 
level of significance, α = 0.025 (one-sided); statistical pow-
er, 1 – β = 0.95; standard deviation = 11; noninferiority 
margin = 5 (10%); and difference between test group and 
comparison group, Δ = 0, δ (> 0) = noninferiority margin. 
The calculated sample size for the noninferiority test (n = 
126 for polmacoxib 2 mg and celecoxib 200 mg and n = 63 
for placebo) was sufficient to fulfill the sample size needed 
for the superiority test for this trial at 93% statistical pow-
er.
Testing between drugs was conducted in the follow-
ing order: (1) test for superiority between placebo versus 
polmacoxib or celecoxib, (2) test for noninferiority us-
ing upper CI between polmacoxib and celecoxib, and (3) 
test for superiority between polmacoxib and celecoxib. 
The primary endpoint was analyzed using a mixed effect 
analysis of covariance (ANCOVA), with terms for site as a 
random explanatory variable, treatment as a fixed explana-
tory variable, and baseline score as a covariate. Noninfe-
riority was based on whether the upper limit of the one-
sided 97.5% CI of the difference between the polmacoxib 2 
mg and celecoxib 200 mg treatment groups, derived from 
the mixed effects ANCOVA, was less than or equal to the 
prespecified noninferiority margin of 10% (5 points on the 
WOMAC-pain subscale). Analysis of variance results were 
reported with least square (LS) means and their standard 
errors for the treatment group results, and estimates, their 
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standard errors, and 95% CIs for treatment differences. 
The secondary endpoints were analyzed using a repeated 
measurement ANCOVA, with terms for site as a random 
explanatory variable, treatment as a fixed explanatory 
variable, and baseline score as a covariate. Noninferiority 
for the secondary endpoints was predefined as 10% of the 
maximum score for each scale or subscale. Noninferiority 
was not evaluated for the SGA and PGA tests.
Continuous demographic parameters were sum-
marized for the ITT population, defined as all randomized 
patients, using descriptive statistics. Categorical demo-
graphic parameters were summarized as a proportion of 
the ITT population. The primary and secondary efficacy 
evaluations were based on the ITT population using 
baseline observation carried forward (BOCF) method, 
regarded as the most conservative imputation method in 
pain subject analysis. Sensitivity analyses were made using 
various imputation methods in all analysis populations. 
All safety data were analyzed using the safety population. 
No data imputation was used for missing safety data. 
Study populations are defined as follows: (1) ITT 
population: all randomized subjects; (2) modified ITT 
population: all randomized subjects who met all inclu-
sion/exclusion criteria, received at least one dose of study 
product and returned for at least one postbaseline visit; (3) 
per-protocol population: all randomized subjects who met 
all inclusion/exclusion criteria, were at least 80% or more 
compliant with the assigned study treatment, returned 
to the study site for the primary endpoint visit within the 
specified time period or withdrew consent due to treat-
ment failure, and had no major protocol violations; (4) 
safety population: all subjects who were administered any 
amount of study product. It was not possible to conduct 
statistical analysis for treatment comparisons beyond week 
6 as there was only a single treatment arm during the 18-
week trial extension.
Ethics
This study was registered with and approved by the Minis-
try of Food and Drug Safety of the Republic of Korea (IND 
11004 CG100649-3-01; ClinicalTrials.gov: NCT01765296) 
and approved by the Independent Ethics Committee and 
Institutional Review Board at each of its 14 study sites: 
Seoul National University Hospital, National Health In-
surance Service Ilsan Hospital, Inje University Seoul Paik 
Hospital, Kyungpook National University Hospital, Asan 
Medical Center, SMG-SNU Boramae Medical Center, 
Hanyang University Seoul Hospital, Samsung Medical 
Center, Chungnam National University Hospital, Korea 
University Anam Hospital, Seoul St. Mary's Hospital, 
Yonsei University, Ewha Womans University Mokdong 
Hospital, and Gachon University Gil Medical Center. All 
subjects provided written informed consent prior to par-
ticipation in the study, and the study was conducted in 
compliance with principles of Good Clinical Practice. 
RESULTS
Patients
The study was conducted in patients with OA at 14 tertia-
ry care centers in Korea from March 25, 2013 to Decem-
ber 9, 2013. Of the 441 subjects screened for this study, 
362 were randomized to three treatment groups as follows: 
71 (16.1%) to placebo, 146 (33.1%) to polmacoxib 2 mg 
once daily, and 145 (32.9%) to celecoxib 200 mg once daily 
(Fig. 1). The majority of subjects in the study were females 
(85.4%) and the average age was 62.4 years (Table 1). All 
subjects were Asian, and the majority had knee joint OA 
(99.2%). Most subjects in each treatment group had ACR 
class II functional status, indicating that they could per-
form usual self-care activities, but had limited function in 
other activities. Alcohol use was limited to < 1 drink daily 
for 87.3% of subjects, and the majority had never smoked 
(95.9%). Other baseline patient demographics, concomi-
tant medications, medical conditions or procedures re-
ported, and baseline scores for efficacy assessments are 
shown in Table 1. 
Efficacy 
Primary efficacy outcome
The LS mean reductions from baseline to week 6 in 
WOMAC-pain subscale scores were significantly greater 
in both the polmacoxib group and the celecoxib group 
than the reduction observed in the placebo group (Tables 
2-4 and Fig. 2A). The difference between the polmacoxib 
and celecoxib groups was not significant. The upper 
bound of the one-sided 97.5% CI was 2.2 (2.1 in the per-
protocol population), less than the prespecified nonin-
feriority margin of 5 for WOMAC-pain subscale. This 
result of noninferiority between polmacoxib and celecoxib 
groups was observed consistently with those from the sen-
sitivity analyses based on different imputation methods. 
Results from the analysis of the per-protocol (Table 4) and 
observed cases without imputation in ITT population (Ta-
ble 3) were also consistent with the results of the analysis 
of ITT population with BOCF imputation (Table 2). 
Secondary efficacy outcomes
ㆍChange in WOMAC-pain subscale at week 3: LS mean 
decreases from baseline were observed in all treatment 
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groups at week 3 (Tables 2-4 and Fig. 2A). The mean 
changes from baseline in both the polmacoxib group and 
the celecoxib group were significantly greater than the 
change observed in the placebo group. The difference 
between the polmacoxib and celecoxib groups was not sta-
tistically significant. Results from the analysis of the per-
protocol population and sensitivity analyses using other 
imputation methods were similar to those observed using 
the BOCF imputation method.
ㆍChange in WOMAC-OA index: LS mean decreases 
from baseline in WOMAC-OA index scores were observed 
in all treatment groups at week 3 (Tables 2-4 and Fig. 2B). 
LS mean decreases from baseline were significantly greater 
in both the polmacoxib group and the celecoxib group 
than the change observed in the placebo group for both 
weeks 3 and 6. 
ㆍChange in WOMAC-stiffness subscale: LS mean de-
creases from baseline in WOMAC-stiffness subscale scores 
were observed in all treatment groups at week 3 (Tables 
2-4 and Fig. 2C). LS mean changes at week 6 were similar 
to those observed at week 3 in all treatment groups. At 
both time points, the LS mean changes in both the polma-
coxib and the celecoxib groups were significantly greater 
than the change observed in the placebo group, while the 
difference between the polmacoxib and celecoxib groups 
was not statistically significant.
ㆍChange in WOMAC-physical function subscale: LS 
mean decreases in WOMAC-physical function subscale 
scores from baseline were observed in all treatment groups 
at week 3 (Tables 2-4 and Fig. 2D). The difference in the 
LS mean change from baseline between the placebo and 
celecoxib groups was not statistically significant at this 
time point, while the difference between the placebo and 
polmacoxib groups was statistically significant. Similar 
results were also observed in all treatment groups in the 
per-protocol (Table 4) and modified ITT populations, and 
in the sensitivity analyses using other imputation meth-
ods, including analysis of observed cases without imputa-
tion. LS mean decreases were also observed at week 6 in 
all treatment groups (Tables 2-4 and Fig. 2D). The mean 
changes from baseline in both polmacoxib and celecoxib 
groups were greater than the change observed in the pla-
cebo group at week 6. The difference between the polma-
coxib and celecoxib groups was not statistically significant. 
Similar results were observed in all analysis populations, 
including all sensitivity analyses. 
ㆍChange in SGA and PGA: Across all treatment groups, 
most subjects reported minimal improvement in their 
condition at week 3 (Table 5). However, 20.0% of subjects 
in the polmacoxib group and 14.9% of subjects in the cele-
coxib group reported their condition as “much improved” 
or “very much improved” by week 3 compared with 3.0% 
of subjects in the placebo group; similar results were ob-
served at week 6 for subjects in the polmacoxib (16.7%), 
celecoxib (12.1%), and placebo (1.5%) groups. 
Based on the PGA, by week 3, 22.9% of subjects in 
the polmacoxib group and 17.1% of subjects in the ce-
lecoxib group were considered by the investigator to be 
“much improved” or “very much improved” compared 
with 4.5% of subjects in the placebo group (Table 5). A 
441 Total screened
79 Screen failure
362 Subjects randomized
71 Placebo 146 Polmacoxib 2 mg 145 Celecoxib 200 mg
5 Discontinued (7.0%)
4 Subject withdrawal
1 Adverse event
20 Discontinued (13.7%)
5 Protocol violation
2 Subject withdrawal
13 Adverse event
13 Discontinued (9.0%)
4 Protocol violation
2 Subject withdrawal
5 Adverse event
2 Lack of efficacy/other
66 Completed (93.0%) 126 Completed (86.3%) 132 Completed (91.0%)
Fig. 1. Subject disposition throughout 
the 6-week period.
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Table 1. Demographic and Baseline Characteristics (ITT Population)
Characteristic Placebo  (n = 71)
Polmacoxib 2 mg 
(n = 146)
Celecoxib 200 mg 
(n = 145)
Total  
(n = 362)
Age (yr)
   Mean ± SD 62.9 ± 9.0 62.5 ± 7.5 62.1 ± 7.6 62.4 ± 7.8
   Median (range) 63 (28–83) 63 (40–78) 62 (44–82) 63 (28–83)
Sex
   Male 10 (14.1) 21 (14.4) 22 (15.2) 53 (14.6)
   Female 61 (85.9) 125 (85.6) 123 (84.8) 309 (85.4)
Race (Asian) 71 146 145 362
Smoking status
   Never 69 (97.2) 139 (95.2) 139 (95.9) 347 (95.9)
   Former 1 (1.4) 5 (3.4) 3 (2.1) 9 (2.5)
   Current 1 (1.4) 2 (1.4) 3 (2.1) 6 (1.7)
Drinking status
   < 1 Drink per day 62 (87.3) 129 (88.4) 125 (86.2) 316 (87.3)
   1–2 Drinks per day 3 (4.2) 2 (1.4) 3 (2.1) 8 (2.2)
   ≥ 3 Drinks per day 6 (8.5) 15 (10.3) 17 (11.7) 38 (10.5)
Concomitant medication
   Anti-inflammatory and anti-rheumatic drugs, non-steroids 28 (39.4) 76 (52.1) 54 (37.2) 158 (43.6)
   Drugs for peptic ulcers and gastroesophageal reflux disease 20 (28.2) 61 (41.8) 28 (19.3) 109 (30.1)
   Lipid-modifying drugs, single agents 14 (19.7) 33 (22.6) 32 (22.1) 79 (21.8)
   Selective calcium channel blockers with mainly vascular effects 14 (19.7) 21 (14.4) 16 (11.0) 51 (14.1)
   Blood glucose-lowering drugs, excluding insulins 12 (16.9) 12 (8.2) 26 (17.9) 50 (13.8)
   Propulsives 8 (11.3) 21 (14.4) 16 (11.0) 45 (12.4)
   Angiotensin II antagonists, combination 6 (8.5) 12 (8.2) 15 (10.3) 33 (9.1)
   Angiotensin II antagonists, plain 4 (5.6) 18 (12.3) 11 (7.6) 33 (9.1)
Medical condition or procedure
   Hypertension 22 (31.0) 55 (37.7) 42 (29.0) 119 (32.9)
   Hyperlipidaemia 10 (14.1) 31 (21.2) 29 (20.0) 70 (19.3)
   Osteoporosis 8 (11.3) 17 (11.6) 13 (9.0) 38 (10.5)
   Diabetes mellitus 8 (11.3) 9 (6.2) 19 (13.1) 36 (9.9)
   Meniscus injury 3 (4.2) 15 (10.3) 17 (11.7) 35 (9.7)
   Gastritis 5 (7.0) 14 (9.6) 13 (9.0) 32 (8.8)
WOMAC-pain subscale
   Mean ± SD 26.8 ± 4.58 27.9 ± 5.01 27.7 ± 5.08 27.6 ± 4.96
   Median (range) 26.0 (20–40) 27.0 (20–40) 27.0 (20–40) 27.0 (20–40)
WOMAC-OA index
   Mean ± SD 129.2 ± 26.52 132.6 ± 26.44 131.6 ± 25.94 131.5 ± 26.21
   Median (range) 130.0 (74–194) 132.0 (72–196) 130.0 (73–197) 131.0 (72–197)
WOMAC-stiffness subscale
   Mean ± SD 10.4 ± 3.52 11.1 ± 3.44 11.1 ± 3.23 10.9 ± 3.37
   Median (range) 11.0 (0–17) 11.0 (0–18) 11.0 (0–18) 11.0 (0–18)
WOMAC-physical function subscale
   Mean ± SD 92.0 ± 19.87 93.6 ± 19.50 92.8 ± 19.26 93.0 ± 19.43
   Median (range) 92.0 (46–139) 92.0 (46–138) 92.0 (51–144) 92.0 (46–144)
Values are presented as number (%) unless otherwise indicated.
ITT: intent-to-treat, SD: standard deviation, WOMAC: Western Ontario and McMaster Universities, OA: osteoarthritis.
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Table 2. Summary Results* of Noninferiority and Superiority Tests on Change in WOMAC Index from Baseline to Weeks 3 and 6 as Primary and 
Secondary Endpoints in ITT Population: Baseline Observation Carried Forward 
Variable
Week 3 Week 6
Placebo 
(n = 71)
Polmacoxib 
2 mg
(n = 146)
Celecoxib 
200 mg 
(n = 145)
Placebo 
(n = 71)
Polmacoxib 
2 mg
(n = 146)
Celecoxib 
200 mg
(n = 145)
WOMAC-pain
LS mean change –2.0 ± 0.85 
(–3.7 to –0.4)
–4.9 ± 0.68 
(–6.2 to –3.6)
–4.4 ± 0.68
 (–5.7 to –3.1)
–2.6 ± 0.90 
(–4.4 to –0.8)
–5.1 ± 0.70
 (–6.5 to –3.7)
–5.7 ± 0.70 
(–7.1 to –4.4)
Comparisons vs. placebo  –2.9 ± 0.87 
(–4.6 to –1.2)
–2.4 ± 0.87 
(–4.1 to –0.7)
–2.5 ± 0.98
 (–4.4 to –0.6)
–3.1 ± 0.98 
(–5.1 to –1.2)
   p-value  0.001 0.007 0.011 0.001
Polmacoxib vs. celecoxib  –0.5 ± 0.70 
(–1.9 to 0.9)
 0.6 ± 0.79 
(–0.9 to 2.2)
 
   p-value  0.471  0.425  
Noninferiority (NI margin = 5) Yes, UCI (0.9) is less than NI margin (5) Yes, UCI (2.2) is less than NI margin (5)
WOMAC-stiffness
LS mean change –0.4 ± 0.32 
(–1.0 to 0.3)
–1.7 ± 0.25
 (–2.2 to –1.2)
–1.2 ± 0.25 
(–1.7 to –0.7)
–0.5 ± 0.42 
(–1.3 to 0.3)
–1.6 ± 0.33 
(–2.3 to –1.0)
–1.7 ± 0.33
 (–2.3 to –1.0)
Comparisons vs. placebo  –1.4 ± 0.36 
(–2.1 to –0.7)
–0.9 ± 0.36 
(–1.6 to –0.2) 
–1.1 ± 0.43 
(–2.0 to –0.3)
–1.2 ± 0.43 
(–2.0 to –0.3)
   p-value  < 0.001 0.014 0.008 0.007
Polmacoxib vs. celecoxib  –0.5 ± 0.29 
(–1.0 to 0.1)
 0.0 ± 0.35 
(–0.7 to 0.7)
 
   p-value  0.102  0.934  
Noninferiority (NI margin = 2) Yes, UCI (0.1) is less than NI margin (2) Yes, UCI (0.7) is less than NI margin (2)
WOMAC-physical function
LS mean change –5.7 ± 2.49 
(–10.6 to –0.8)
–13.7 ± 1.92 
(–17.5 to –9.9)
–10.7 ± 1.92 
(–14.5 to –6.9)
–7.9 ± 2.83 
(–13.4 to –2.3)
–14.3 ± 2.18 
(–18.6 to –10.0) 
–14.9 ± 2.18 
(–19.1 to –10.6)
Comparisons vs. placebo  –8.0 ± 2.71
 (–13.3 to –2.6)
–5.0 ± 2.71 
(–10.3 to 0.4)
–6.5 ± 3.08 
(–12.5 to –0.4)
–7.0 ± 3.08 
(–13.1 to –0.9)
   p-value  0.003 0.069 0.036 0.024
Polmacoxib vs. celecoxib  –3.0 ± 2.20 
(–7.3 to 1.3)
 0.5 ± 2.49 
(–4.4 to 5.4)
 
   p-value  0.17  0.833  
Noninferiority (NI margin = 17) Yes, UCI (1.3) is less than NI margin (17) Yes, UCI (5.4) is less than NI margin (17)
WOMAC-OA index
LS mean change –8.0 ± 3.51 
(–14.9 to –1.1)
–20.4 ± 2.73 
(–25.8 to –15.0) 
–16.4 ± 2.73
 (–21.7 to –11.0)
–10.8 ± 3.97 
(–18.6 to –3.0)
–21.2 ± 3.07 
(–27.2 to –15.2) 
–22.4 ± 3.07 
(–28.4 to –16.3)
Comparisons vs. placebo  –12.4 ± 3.77 
(–19.8 to –5.0)
–8.3 ± 3.77 
(–15.8 to –0.9)
–10.4 ± 4.31 
(–18.8 to –1.9)
–11.5 ± 4.31 
(–20.0 to –3.1) 
   p-value  0.001 0.027 0.016 0.008
Polmacoxib vs. celecoxib  –4.0 ± 3.05 
(–10.0 to 2.0)
 1.2 ± 3.48
 (–5.7 to 8.0)
 
   p-value  0.187  0.740  
Noninferiority (NI margin = 24) Yes, UCI (2.0) is less than NI margin (24) Yes, UCI (8.0) is less than NI margin (24)
Values are presented as mean ± standard error (95% confidence interval).
WOMAC: Western Ontario and McMaster Universities, ITT: intent-to-treat, LS: least square, NI: noninferiority, UCI: upper confidence interval, OA: osteoarthritis. 
*Data obtained from a mixed-effects analysis of covariance model with fixed effects for treatment group and baseline pain score and a random effect for pooled 
site.
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Table 3. Summary Results* of Noninferiority and Superiority Tests on Change in WOMAC Index from Baseline to Weeks 3 and 6 as Primary and 
Secondary Endpoints in ITT Population: Observed Cases
Variable
Week 3 Week 6
Placebo 
(n = 67)
Polmacoxib 
2 mg 
(n = 135)
Celecoxib 
200 mg
(n = 134)
Placebo 
(n = 66)
Polmacoxib 
2 mg 
(n = 126)
Celecoxib 
200 mg 
(n = 132)
WOMAC-pain
LS mean change –2.2 ± 0.90 
(–3.9 to –0.4)
–5.3 ± 0.74 
(–6.7 to –3.8)
–4.8 ± 0.74 
(–6.2 to –3.3)
–2.7 ± 1.02
 (–4.7 to –0.7)
–6.0 ± 0.84 
(–7.6 to –4.3)
–6.3 ± 0.83 
(–7.9 to –4.7)
Comparisons vs. placebo  –3.1 ± 0.90 
(–4.9 to –1.3)
–2.6 ± 0.90 
(–4.4 to –0.9)
–3.2 ± 1.03 
(–5.3 to –1.2)
–3.6 ± 1.02 
(–5.6 to –1.6)
   p-value  0.001 0.004 0.002 0.001
Polmacoxib vs. celecoxib  –0.5 ± 0.73 
(–1.9 to 0.9)
 0.4 ± 0.85 
(–1.3 to 2.0)
 
   p-value  0.501  0.669  
Noninferiority (NI margin = 5) Yes, UCI (0.9) is less than NI margin (5) Yes, UCI (2.0) is less than NI margin (5)
WOMAC-stiffness
LS mean change –0.3 ± 0.34 
(–1.0 to 0.4)
–1.9 ± 0.26 
(–2.4 to –1.3)
–1.4 ± 0.26 
(–1.9 to –0.8)
–0.5 ± 0.45 
(–1.4 to 0.4)
–1.9 ± 0.38 
(–2.7 to –1.2)
–1.9 ± 0.37 
(–2.6 to –1.2) 
Comparisons vs. placebo  –1.6 ± 0.37 
(–2.3 to –0.8)
–1.0 ± 0.37 
(–1.8 to –0.3)
–1.5 ± 0.46 
(–2.4 to –0.6)
–1.4 ± 0.45 
(–2.3 to –0.5)
   p-value  < 0.001 0.005 0.002 0.002
Polmacoxib vs. celecoxib  –0.5 ± 0.30 
(–1.1 to 0.1)
 –0.0 ± 0.37 
(–0.8 to 0.7)
 
   p-value  0.094  0.941  
Noninferiority (NI margin = 2) Yes, UCI (0.1) is less than NI margin (2) Yes, UCI (0.7) is less than NI margin (2)
WOMAC-physical function
LS mean change –6.1 ± 2.67 
(–11.3 to –0.8) 
–14.9 ± 2.11 
(–19.0 to –10.7)
–11.6 ± 2.11 
(–15.7 to –7.4)
–8.4 ± 3.17 
(–14.6 to –2.1)
–16.7 ± 2.59 
(–21.8 to –11.6)
–16.2 ± 2.56 
(–21.3 to –11.2)
Comparisons vs. placebo  –8.8 ± 2.85 
(–14.4 to –3.2)
–5.5 ± 2.85 
(–11.1 to 0.1)
–8.3 ± 3.29 
(–14.8 to –1.9)
–7.9 ± 3.26 
(–14.3 to –1.5)
   p-value  0.002 0.055 0.012 0.016
Polmacoxib vs. celecoxib  –3.3 ± 2.32 
(–7.8 to 1.3)
 –0.4 ± 2.70 
(–5.8 to 4.9)
 
   p-value  0.16  0.868  
Noninferiority (NI margin = 17) Yes, UCI (1.3) is less than NI margin (17) Yes, UCI (4.9) is less than NI margin (17)
WOMAC-OA index
LS mean change –8.5 ± 3.75 
(–15.9 to –1.1)
–22.1 ± 2.99 
(–28.0 to –16.2)
–17.8 ± 2.99 
(–23.7 to –11.9)
–11.5 ± 4.46 
(–20.3 to –2.7)
–24.7 ± 3.66 
(–31.9 to –17.5)
–24.5 ± 3.61 
(–31.6 to –17.4)
Comparisons vs. placebo  –13.6 ± 3.94 
(–21.3 to –5.8)
–9.3 ± 3.94 
(–17.0 to –1.5)
–13.2 ± 4.59 
(–22.2 to –4.2)
–13.0 ± 4.55 
(–22.0 to –4.1)
   p-value  0.001 0.019 0.004 0.004
Polmacoxib vs. celecoxib  –4.3 ± 3.21
(–10.6 to 2.0)
 –0.2 ± 3.76 
(–7.5 to 7.2)
 
   p-value  0.183  0.967  
Noninferiority (NI margin = 24) Yes, UCI (2.0) is less than NI margin (24) Yes, UCI (7.2) is less than NI margin (24)
Values are presented as mean ± standard error (95% confidence interval).
WOMAC: Western Ontario and McMaster Universities, ITT: intent-to-treat, LS: least square, NI: noninferiority, UCI: upper confidence interval, OA: osteoarthritis. 
*Data obtained from a mixed-effects analysis of covariance model with fixed effects for treatment group and baseline pain score and a random effect for pooled 
site. 
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Table 4. Summary Results* of Noninferiority and Superiority Tests on Change in WOMAC Index from Baseline to Weeks 3 and 6 as Primary and 
Secondary Endpoints in Per-Protocol Population
Variable
Week 3 Week 6
Placebo 
(n = 61)
Polmacoxib 
2 mg 
(n = 112)
Celecoxib 
200 mg 
(n = 121)
Placebo 
(n = 61)
Polmacoxib 
2 mg 
(n = 112)
Celecoxib 
200 mg 
(n = 121)
WOMAC-pain
LS mean change –2.3 ± 0.99 
(–4.3 to –0.4)
–5.4 ± 0.84 
(–7.0 to –3.7)
–5.0 ± 0.82 
(–6.6 to –3.4) 
–2.6 ± 1.07 
(–4.7 to –0.5)
–6.3 ± 0.89 
(–8.0 to –4.6)
–6.6 ± 0.87 
(–8.3 to –4.9)
Comparisons vs. placebo  –3.0 ± 0.99 
(–5.0 to –1.1)
–2.7 ± 0.98
 (–4.6 to –0.8)
–3.7 ± 1.12 
(–5.9 to –1.5)
–4.0 ± 1.11 
(–6.2 to –1.8)
   p-value  0.002 0.006 0.001 < 0.001
Polmacoxib vs. celecoxib  –0.3 ± 0.81 
(–1.9 to 1.3)
 0.3 ± 0.92 
(–1.5 to 2.1)
 
   p-value  0.682  0.727  
Noninferiority (NI margin = 5) Yes, UCI (1.3) is less than NI margin (5) Yes, UCI (2.1) is less than NI margin (5)
WOMAC-stiffness
LS mean change –0.4 ± 0.37 
(–1.1 to 0.4)
–1.9 ± 0.29 
(–2.5 to –1.3)
–1.5 ± 0.28
 (–2.1 to –0.9)
–0.6 ± 0.49 
(–1.6 to 0.3)
–2.1 ± 0.41 
(–2.9 to –1.3)
–2.1 ± 0.40 
(–2.9 to –1.3)
Comparisons vs. placebo  –1.6 ± 0.41 
(–2.4 to –0.7)
–1.2 ± 0.41 
(–2.0 to –0.4)
–1.5 ± 0.48 
(–2.4 to –0.5)
–1.4 ± 0.48 
(–2.4 to –0.5)
   p–value  < 0.001 0.005 0.003 0.003
Polmacoxib vs. celecoxib  –0.4 ± 0.34 
(–1.1 to 0.3)
 0.0 ± 0.40 
(–0.8 to 0.8)
 
   p-value  0.24  0.962  
Noninferiority (NI margin = 2) Yes, UCI (0.3) is less than NI margin (2) Yes, UCI (0.8) is less than NI margin (2)
WOMAC-physical function
LS mean change –6.6 ± 2.90 
(–12.3 to –0.9)
–14.7 ± 2.35 
(–19.3 to –10.1)
–11.7 ± 2.29 
(–16.2 to –7.2)
–8.4 ± 3.33 
(–15.0 to –1.8)
–17.4 ± 2.71
 (–22.7 to –12.0)
–17.1 ± 2.64 
(–22.3 to –11.9)
Comparisons vs. placebo  –8.1 ± 3.15 
(–14.3 to –1.9)
–5.1 ± 3.11 
(–11.2 to 1.0)
–9.0 ± 3.59 
(–16.0 to –1.9)
–8.7 ± 3.54 
(–15.6 to –1.7)
   p-value  0.011 0.1 0.013 0.015
Polmacoxib vs. celecoxib  –3.0 ± 2.59 
(–8.1 to 2.1)
 –0.3 ± 2.96 
(–6.1 to 5.5)
 
   p-value  0.254  0.917  
Noninferiority (NI margin = 17) Yes, UCI (2.1) is less than NI margin (17) Yes, UCI (5.5) is less than NI margin (17)
WOMAC-OA index
LS mean change –9.3 ± 4.08 
(–17.3 to –1.2)
–22.1 ± 3.34 
(–28.6 to –15.5)
–18.3 ± 3.25 
(–24.7 to –11.9)
–11.5 ± 4.68 
(–20.8 to –2.3)
–25.9 ± 3.83 
(–33.4 to –18.3)
–25.8 ± 3.74 
(–33.2 to –18.5)
Comparisons vs. placebo  –12.8 ± 4.36 
(–21.4 to –4.2)
–9.1 ± 4.30 
(–17.5 to –0.6)
–14.3 ± 5.00 
(–24.2 to –4.5)
–14.3 ± 4.93
(–24.0 to –4.6)
   p-value  0.004 0.036 0.004 0.004
Polmacoxib vs. celecoxib  –3.7 ± 3.59 
(–10.8 to 3.3)
 –0.1 ± 4.11 
(–8.2 to 8.0)
 
   p-value  0.299  0.988  
Noninferiority (NI margin = 24) Yes, UCI (3.3) is less than NI margin (24) Yes, UCI (8.0) is less than NI margin (24)
Values are presented as mean ± standard error (95% confidence interval).
WOMAC: Western Ontario and McMaster Universities, ITT: intent-to-treat, LS: least square, NI: noninferiority, UCI: upper confidence interval, OA: osteoarthritis. 
*Data obtained from a mixed-effects analysis of covariance model with fixed effects for treatment group and baseline pain score and a random effect for pooled 
site. 
449
Lee et al. Phase III Efficacy and Safety of Polmacoxib for Osteoarthritis
Clinics in Orthopedic Surgery • Vol. 9, No. 4, 2017 • www.ecios.org
similar trend was observed at week 6 in all treatment 
groups. A slightly higher proportion of subjects in the 
polmacoxib group (18.3%) compared with the celecoxib 
group (12.9%) were considered to be “much improved” 
and “very much improved” by week 6. Only 4.5% of sub-
jects in the placebo group were considered to be as such. 
Withdrawal due to lack of analgesic efficacy
Only one subject, who was treated with celecoxib, with-
drew from the study owing to a lack of analgesic efficacy.
Fig. 2. Efficacy endpoints among treatment groups: least square (LS) mean changes from baseline in the WOMAC-pain subscale (A), total WOMAC-
OA index score (B), WOMAC-stiffness subscale (C), and WOMAC-physical function subscale (D) at weeks 3 and 6 (intent-to-treat population, baseline 
observation carried forward). Data shown below the brackets are estimated treatment differences with 95% confidence intervals and p-values. The text 
in red indicates the upper confidence interval. Noninferiority can be inferred, as the predefined noninferiority margin for the WOMAC-pain subscale (A) 
was a score of 5 (10% of the total score), total WOMAC-OA index (B) was a score of 24 (10% of the total score), WOMAC-stiffness subscale (C) was a 
score of 2 (10% of the total score), and WOMAC-physical function subscale (D) was a score of 17 (10% of the total score). WOMAC: Western Ontario 
and McMaster Universities, OA: osteoarthritis.
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Safety 
Overall, 79 subjects (21.8%) experienced at least one 
TEAE during the 6-week treatment period. The incidence 
of TEAEs (95% CI) was 28.6% (21.4% to 36.6%) in the 
polmacoxib group, 18.8% (12.7% to 26.1%) in the celecox-
ib group and 14.1% (7.0% to 24.4%) in the placebo group. 
TEAEs relating to GI disorders and general disorders 
occurred with a numerically greater frequency in the pol-
macoxib and celecoxib groups compared with the placebo 
group (Table 6). The difference in TEAEs was primarily 
influenced by a few events of peripheral edema, edema, 
and abdominal pain that occurred more frequently in the 
polmacoxib group. However, all of these events occurred 
in < 5% of subjects.
Similarly, the most commonly reported TEAEs 
considered to be related to treatment in the polmacoxib 
and celecoxib groups were associated with GI and general 
disorders (Table 7). These events, however, were reported 
Table 5. Change from Baseline at Week 3 in the Subject’s Global Assessment and Physician’s Global Assessment (ITT Population-Observed Cases 
and Per-Protocol Population)
Variable 
ITT population (week 3) Per-protocol population (week 3)
Placebo
(n = 71)
Polmacoxib 
2 mg
(n = 146)
Celecoxib 
200 mg
(n = 145)
Placebo
(n = 71)
Polmacoxib 
2 mg
(n = 146)
Celecoxib 
200 mg
(n = 145)
Subject’s Global Assessment
   Number 67 135 134 61 112 121
   Very much improved 0 0 2 (1.5) 0 0 2 (1.7)
   Much improved 2 (3.0) 27 (20.0) 18 (13.4) 2 (3.3) 23 (20.5) 18 (14.9)
   Minimally improved 33 (49.3) 74 (54.8) 65 (48.5) 32 (52.5) 60 (53.6) 59 (48.8)
   No change 24 (35.8) 29 (21.5) 44 (32.8) 20 (32.8) 24 (21.4) 37 (30.6)
   Minimally worse  7 (10.4) 3 (2.2) 4 (3.0) 6 (9.8) 3 (2.7) 4 (3.3)
   Much worse 1 (1.5) 2 (1.5) 1 (0.7) 1 (1.6) 2 (1.8) 1 (0.8)
   Very much worse  - - -  - - - 
   Comparisons vs. placebo (p-value)*  < 0.001 0.013  0.001 0.025
   Polmacoxib vs. celecoxib (p-value)*  0.058  0.189  
Physician’s Global Assessment
   Number 67 135 134 61 112 121
   Very much improved 0 1 (0.7) 1 (0.7) 0 1 (0.9) 1 (0.8)
   Much improved 3 (4.5) 30 (22.2) 22 (16.4) 3 (4.9) 27 (24.1) 22 (18.2)
   Minimally improved 30 (44.8) 74 (54.8) 56 (41.8) 29 (47.5) 58 (51.8) 51 (42.1)
   No change 29 (43.3) 28 (20.7) 51 (38.1) 24 (39.3) 24 (21.4) 43 (35.5)
   Minimally worse 5 (7.5) 1 (0.7) 3 (2.2) 5 (8.2) 1 (0.9) 3 (2.5)
   Much worse 0 1 (0.7) 1 (0.7) 0 1 (0.9) 1 (0.8)
   Very much worse  - - - - - - 
   Comparisons vs. placebo (p-value)*  < 0.001 0.034  <0.001 0.042
   Polmacoxib vs. celecoxib (p-value)*  0.003  0.020  
Values are presented as number (%).
ITT: intent-to-treat.
*p-values obtained from an ordinal logistic regression model with effects for treatment and pooled site.
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for ≤ 2% of subjects in both treatment groups. The GI 
events with a “probable” relationship to polmacoxib treat-
ment were abdominal pain (one subject), upper abdomi-
nal pain (one subject), diarrhea (one subject), enteritis 
(one subject) and dyspepsia (two subjects). Other TEAEs 
with a “possible” or “probable” relationship to polmacoxib 
treatment included face edema, edema, peripheral edema, 
headache, face swelling, urticaria, pruritus and increased 
blood creatinine. The GI disorders with a “probable” or 
“possible” relationship to celecoxib treatment were up-
per abdominal pain (three subjects) and dyspepsia (two 
subjects). Other TEAEs with a “possible” or “probable” 
relationship to celecoxib treatment included generalized 
edema, peripheral edema, headache, somnolence, and 
depression. One subject in the celecoxib group had upper 
abdominal pain considered to have a “certain” relationship 
to treatment; there were no such TEAEs in the polmacoxib 
group.
Across all treatment groups, most TEAEs were mild 
in intensity. Events reported as moderate in intensity oc-
curred with a similar frequency in all treatment groups. 
Severe events occurred in 4.1% of subjects in the polma-
Table 6.  Treatment-Emergent Adverse Events Occurring in ≥ 2% of Subjects by Treatment Group and Preferred Term during the 6-Week Treatment 
Period (Safety Population)
System Organ Class 
Preferred Term
Placebo 
(n = 71)
Polmacoxib 2 mg 
(n = 147)*
Celecoxib 200 mg 
(n = 144)*
Gastrointestinal disorders 3 (4.2) 15 (10.2) 14 (9.7)
   Comparisons vs. placebo (p-value)† 0.190 0.189
   Polmacoxib vs. celecoxib (p-value)† 1.000
   Abdominal pain 1 (1.4) 3 (2.0) 0 
   Diarrhoea 0 3 (2.0) 3 (2.1)
   Dyspepsia 1 (1.4) 7 (4.8) 5 (3.5)
   Abdominal pain, upper 1 (1.4) 1 (0.7) 4 (2.8)
General disorders and administration site conditions 2 (2.8) 16 (10.9) 8 (5.6) 
   Comparisons vs. placebo (p-value)† 0.063 0.503
   Polmacoxib vs. celecoxib (p-value)† 0.135
   Face oedema 1 (1.4) 3 (2.0) 2 (1.4) 
   Oedema 0 4 (2.7) 0 
   Oedema peripheral 0 7 (4.8) 3 (2.1) 
Musculoskeletal and connective tissue disorders 3 (4.2) 2 (1.4) 2 (1.4) 
   Comparisons vs. placebo (p-value)† 0.333 0.335
   Polmacoxib vs. celecoxib (p-value)† 1.000
   Musculoskeletal pain 2 (2.8) 0 0 
Skin and subcutaneous tissue disorders 2 (2.8) 5 (3.4) 2 (1.4) 
   Comparisons vs. placebo (p-value)† 1.000 0.600
   Polmacoxib vs. celecoxib (p-value)† 0.448
   Urticaria 2 (2.8) 1 (0.7) 0 
   Swelling face 0 3 (2.0) 0 
Values are presented as number (%).
*Due to an error from one site, one subject was administered with polmacoxib instead of celecoxib. Safety results are therefore presented based on the actual 
number of subjects treated with the drug. This error did not make any numerical differences in the presentation of results. †p-values obtained from Fisher exact 
test.
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Table 7.  Treatment-Emergent Adverse Events by System Organ 
Class, Preferred Term and Relationship to Treatment 
(Certain, Probable, Possible) during the 6-Week Treatment 
Period (Safety Population)
System Organ Class 
Preferred Term and 
Relationship
Placebo 
(n = 71)
Polmacoxib 
2 mg 
(n = 147)
Celecoxib 
200 mg 
(n = 144)
Gastrointestinal disorders 3 (4.2) 15 (10.2) 14 (9.7)
            Certain 0 0  1 (0.7)
            Probable 1 (1.4) 4 (2.7)  2 (1.4)
            Possible 1 (1.4) 2 (1.4)  1 (0.7)
      Abdominal pain 1 (1.4) 3 (2.0) 0 
            Probable 0 1 (0.7) 0 
      Abdominal pain, upper 1 (1.4) 1 (0.7) 4 (2.8)
            Certain 0 0 1 (0.7)
            Probable 0 1 (0.7) 2 (1.4)
            Possible 1 (1.4) 0 1 (0.7)
      Diarrhea 0 3 (2.0) 3 (2.1)
            Probable 0 1 (0.7) 0
      Dyspepsia 1 (1.4) 7 (4.8) 5 (3.5)
            Probable 1 (1.4) 2 (1.4) 1 (0.7)
            Possible 0 1 (0.7) 1 (0.7)
      Enteritis 0 1 (0.7) 0
            Probable 0 1 (0.7) 0 
      Epigastric discomfort 0 1 (0.7) 0
            Possible 0 1 (0.7) 0
General disorders and    
   administration site 
   conditions
2 (2.8) 16 (10.9) 8 (5.6)
            Probable 0 2 (1.4) 1 (0.7)
            Possible 0 4 (2.7) 2 (1.4)
      Face oedema 1 (1.4) 3 (2.0) 2 (1.4)
            Probable 0 2 (1.4) 0 
      Generalized oedema 0 2 (1.4) 1 (0.7)
            Probable 0 0 1 (0.7)
      Oedema 0 4 (2.7) 0 
            Possible 0 3 (2.0) 0 
      Oedema, peripheral 0 7 (4.8) 3 (2.1)
            Probable 0 2 (1.4) 0 
            Possible 0 1 (0.7) 2 (1.4)
Table 7.  Continued
System Organ Class 
Preferred Term and 
Relationship
Placebo 
(n = 71)
Polmacoxib 
2 mg 
(n = 147)
Celecoxib 
200 mg 
(n = 144)
Investigation 1 (1.4) 3 (2.0) 2 (1.4)
            Possible 1 (1.4) 1 (0.7) 0 
      Alanine aminotransferase 
         increased
1 (1.4) 0 0 
            Possible 1 (1.4) 0 0 
      Aspartate aminotransferase 
         increased
1 (1.4) 0 0 
            Possible 1 (1.4) 0 0 
      Blood creatinine increased 0 1 (0.7) 0 
            Possible 0 1 (0.7) 0 
      Gamma-glutamyltransferase 
         increased
1 (1.4) 0 0 
            Possible 1 (1.4) 0 0 
Nervous system disorders 0 1 (0.7) 5 (3.5)
            Possible 0 1 (0.7) 1 (0.7)
      Headache 0 1 (0.7) 2 (1.4)
            Possible 0 1 (0.7) 1 (0.7)
      Somnolence 0 0 1 (0.7)
            Possible 0 0 1 (0.7)
Psychiatric disorders 0 0 1 (0.7)
            Possible 0 0 1 (0.7)
      Depression 0 0 1 (0.7)
            Possible 0 0 1 (0.7)
Skin and subcutaneous 
   tissue disorders
2 (2.8) 5 (3.4) 2 (1.4)
            Possible 1 (1.4) 3 (2.0) 0 (0.0)
      Pruritus 1 (1.4) 1 (0.7) 1 (0.7)
            Possible 0 1 (0.7) 0 
      Swelling face 0 3 (2.0) 0 
            Possible 0 1 (0.7) 0 
      Urticaria 2 (2.8) 1 (0.7) 0 
            Possible 1 (1.4) 1 (0.7) 0 
Values are presented as number (%).
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coxib treatment group (hypertension, abdominal pain, di-
arrhea, gastritis, and spinal compression fracture), 0.7% of 
subjects in the celecoxib group (increased blood pressure), 
and 1.4% of subjects in the placebo group (spinal column 
stenosis). Of the TEAEs occurring in the polmacoxib 
group, only abdominal pain and diarrhea were deemed re-
lated to treatment. There were no deaths during the study 
and SAEs were reported in four subjects, none of which 
were reported as related to treatment.
More subjects treated with polmacoxib discontinued 
the study drug due to TEAEs (9.5% for polmacoxib and 
2.8% for celecoxib and placebo); however, investigators de-
termined that the AEs were not related or unlikely related 
to the study drug. The observed difference in treatment 
discontinuation was primarily influenced by GI disorders 
in three more subjects treated with polmacoxib (3.4%) 
than in subjects treated with celecoxib (1.4%). 
There were no clinically relevant findings in the 
analysis of clinical laboratory tests, vital signs, electrocar-
diograms, or physical examination results. Ten subjects 
experienced changes from baseline in corrected QT inter-
val by Fridericia (QTcF) greater than 30 ms at week 6: two 
of these subjects were treated with polmacoxib; three were 
treated with placebo; and five were treated with celecoxib. 
One subject in the celecoxib group experienced a change 
in QTcF interval from baseline to week 6 of greater than 
78 ms.
Results from the Extended Observation Period
Of the 324 subjects who completed the 6-week treatment 
period, 303 (93.5%) participated in the extended observa-
tion period and received at least one dose of polmacoxib 
2 mg once daily. Originally, 62 had been randomized to 
receive placebo (placebo/polmacoxib), 116 to receive pol-
macoxib 2 mg once daily (polmacoxib/polmacoxib) and 
125 to receive celecoxib 200 mg once daily (celecoxib/pol-
macoxib). A total of 220 subjects (72.6%) completed the 
18-week trial extension.
The results observed during the 18-week safety ex-
tension were consistent with those observed during the 
6-week treatment period. The incidences (95% CIs) of 
TEAEs over 24 weeks were similar between groups: pla-
cebo/polmacoxib, 38.0% (19.0% to 37.5%); polmacoxib/
polmacoxib, 47.6% (26.1% to 38.9%); and celecoxib/pol-
macoxib, 45.8% (25.2% to 38.2%). There were no statisti-
cally significant differences among these three groups (p = 
0.693). Overall, 12.7% of subjects had at least one AE that 
led to study drug discontinuation; although fewer subjects 
(8.5%) in the placebo/polmacoxib group had AEs leading 
to study drug discontinuation compared to subjects in the 
polmacoxib/polmacoxib group (13.6%) and the celecoxib/
polmacoxib group (13.9%), the differences were not statis-
tically significant (p = 0.535).
In particular, the most frequently occurring TEAEs 
over the combined 24-week treatment period (abdominal 
pain, 7.2%; dyspepsia, 6.1%) were reported in 6.9% and 
3.3% of subjects, respectively, during the 18-week safety 
extension. Peripheral edema, which was reported in 3.6% 
of subjects over the combined period, occurred in 1.0% 
of subjects during the safety extension period. There were 
no notable increases in the incidence of any TEAEs. Dur-
ing the 18-week extension, seven SAEs were reported: 
SAEs of angina pectoris, palpitations, and dyspnea were 
reported in the polmacoxib/polmacoxib group, and SAEs 
of pneumonia, concussion, contusion, ruptured ligament, 
and ligament sprain were reported in the celecoxib/pol-
macoxib group. None of the SAEs were considered by the 
investigator to be related to the study drug. There were no 
deaths during the trial extension.
The improvements from baseline in WOMAC 
subscale scores were maintained over 24 weeks in the 
polmacoxib/polmacoxib group (Fig. 3). Subjects initiat-
ing polmacoxib after 6 weeks (placebo/polmacoxib and 
celecoxib/polmacoxib groups) experienced numerical 
improvements in WOMAC subscale scores during the 18-
week trial extension (Fig. 3).
DISCUSSION
In this study, we investigate the safety and efficacy of a new 
pain relief drug, polmacoxib, which was developed with 
the intent to reduce the risk of side effects associated with 
most NSAIDs. Patients with OA were given polmacoxib, 
placebo, or celecoxib (the current standard for moderate to 
serious pain relief from OA). An evaluation was done after 
6 weeks of treatment to assess the patients’ pain, stiffness, 
and physical function using a specially designed question-
naire for OA assessment. The goal was to assess whether 
polmacoxib performs better in terms of improving OA 
signs and symptoms including lowering pain compared 
to placebo, and whether polmacoxib has similar perfor-
mance to celecoxib. We also investigated long-term safety 
concerns. This trial has demonstrated that polmacoxib 
2 mg once daily has analgesic superiority to placebo and 
analgesic noninferiority to celecoxib 200 mg once daily 
in patients with OA over 6 weeks. Treatment effects were 
confirmed by various sensitivity analyses, including per-
protocol population and observed cases without imputa-
tion for missing values. 
The difference in LS mean change in WOMAC-pain 
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at week 6 between polmacoxib and placebo was –2.5 (95% 
CI, –4.4 to –0.6) based on the ITT (BOCF) population, 
and –3.7 (95% CI, –5.9 to –1.5) based on the per-protocol 
population. Although these differences are statistically 
significant (p = 0.011 and p = 0.001, respectively), these 
changes can be interpreted as minimal. However, overall 
improvements in OA signs and symptoms were reported 
by both subjects and physicians and were evident in the 
WOMAC-stiffness and WOMAC-physical function sub-
scales, which evaluated difficulty in performing daily ac-
tivities using questions such as “how much difficulty have 
you had while going up stairs?” In addition, a placebo ef-
fect can be observed, as the placebo group showed a 9.6% 
reduction in pain from baseline to week 6 in per-protocol 
population compared with a 23.0% reduction in the pol-
macoxib group. As a result, the 9.6% reduction for placebo 
should not be interpreted as a baseline score for clinical 
improvement for polmacoxib or celecoxib. The perception 
of pain is subjective and as WOMAC-pain scores are con-
sidered the most objective method of quantifying clinical 
improvements in pain, statistically significant improve-
ments in scores were considered to be clinically relevant.
The difference in LS mean change in WOMAC-pain 
scores between polmacoxib and celecoxib from baseline 
to week 6 was 0.6 (95% CI, –0.9 to 2.2, p = 0.425) based on 
ITT (BOCF) population, with the upper CI of 2.2 clearly 
within the prespecified noninferiority margin of 5. The use 
of BOCF in efficacy analyses to manage treatment discon-
tinuation can be limiting; baseline observation is treated 
as the missing data point for a patient without considering 
the reason for withdrawal from the trial. As such, all com-
binations of imputation and analysis population were used 
to confirm the results of the trial, obtaining similar results 
and conclusions.
Fig. 3. Efficacy endpoints among treatment groups: mean WOMAC questionnaire scores by time point and treatment group (intent-to-treat population). 
(A) WOMAC-pain subscale. (B) Total WOMAC-OA index score. (C) WOMAC-stiffness subscale. (D) WOMAC-physical function subscale. WOMAC: 
Western Ontario and McMaster Universities, OA: osteoarthritis.
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After 3 weeks, polmacoxib was associated with sig-
nificantly superior PGA scores compared with celecoxib, 
indicating that physicians perceived greater patient im-
provements in terms of OA signs and symptoms. These 
findings suggest that polmacoxib 2 mg provides rapid 
relief from OA signs and symptoms and may have a faster 
onset of action than celecoxib. It is noteworthy that these 
effects with polmacoxib were observed at the low dose of 
2 mg per day, the lowest effective dose among all known 
NSAIDs. 
The TEAEs reported in this study were generally 
mild and of the type expected for COX-2 inhibitor drugs. 
The most commonly occurring TEAEs in the polmacoxib 
and celecoxib groups were GI-related, which occurred 
more frequently in both treatment groups when compared 
with the placebo group. As polmacoxib had similar safety 
profiles with celecoxib and other COX-2 inhibitors that 
have shown a reduced incidence of GI disorders com-
pared with other NSAIDs,8) polmacoxib was considered to 
have an acceptable GI safety profile in this study. Besides 
p-values for comparison for the occurrences of adverse 
events between polmacoxib and celecoxib (Table 6), we 
set no higher than the 5% incidence rate for any adverse 
events to be an “acceptable” safety profile for polmacoxib. 
Through extensive literature review on celecoxib in simi-
lar and lager studies, we considered this 5% limit could 
be applicable for polmacoxib as an “acceptable” safety 
profile. The increased edema observed with polmacoxib 
is associated with the well-known side effects of NSAIDs: 
increased sodium and fluid retention due to the reduction 
of prostaglandin28) often leads to mild general peripheral 
edema within the first few weeks of therapy. In this study, 
incidences of peripheral edema (< 5%) in subjects treated 
with polmacoxib were observed within the first 2 weeks 
of therapy, with most subjects recovering within a week 
without any intervention. To further evaluate the safety 
of polmacoxib in patients with OA, a trial extension was 
conducted in which all participants received open-label 
polmacoxib 2 mg daily and were followed for up to 26 
weeks, including an off-treatment period of 2 weeks. Over 
this 6-month period, polmacoxib was well tolerated and 
demonstrated an acceptable profile that was comparable 
to the 6-week treatment period and other available COX-2 
inhibitors.8) In addition, over the safety extension, periph-
eral edema did not occur in the polmacoxib-only group, 
with three events observed in subjects who switched from 
celecoxib (n = 2) and placebo (n = 1).
A limitation of this trial is its relatively short dura-
tion. The main treatment period of 6 weeks with active 
comparator and placebo groups was considered sufficient 
to evaluate the treatment differences among study groups 
and to satisfy the OA guidelines provided by Ministry 
of Food and Drug Safety of Korea. However, additional 
follow-up is needed to establish the long-term efficacy and 
safety of polmacoxib, including its CV safety profile. This 
study was also limited by the fact that all patients were 
Korean, and many were female. Further studies with larger 
and more diverse populations are needed to extrapolate 
these findings to different populations. In addition, the re-
sults of this study were limited to knee joint OA only due 
to very low enrolment of patients with hip joint OA. The 
prevalence of hip joint OA is low among the Korean com-
munity compared with knee or hand OA.29,30) 
In conclusion, polmacoxib 2 mg was relatively well 
tolerated and demonstrated superior efficacy to placebo 
and noninferior efficacy to celecoxib after 6 weeks of treat-
ment in patients with OA. The results obtained during the 
additional 18-week trial extension with polmacoxib 2 mg 
were consistent with those observed during the 6-week 
treatment period, indicating that polmacoxib can be 
considered safe for long-term use based on this relatively 
small scale of study with a Korean population. More im-
portantly, the results of this study showed that polmacoxib 
has the potential to be used as a pain relief drug with re-
duced GI side effects compared to traditional NSAIDs for 
OA.
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